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Developing and piloting a standard framework tool to assess risk of contamination in 
psychological therapy trial protocols in mental healthcare 
 
Abstract 
Objective: The objective of this study was to develop and pilot a standard framework which could be 
used to assess risk of contamination in psychological therapy trials, at the protocol development stage. 
Study Design and Setting: We developed and piloted a risk of contamination framework on a sample 
of 100 psychological therapy trial protocols registered on the ISRCTN registry (www.isrctn.com).  
We assessed all protocols as being low- or high-risk via three possible sources of contamination; 1) 
participant in control arm, 2) participant in intervention arm, 3) therapist in intervention arm.   
Results: Overall, we found that the risk of contamination across all 3 sources was low for most 
studies (86/100 trial protocols; 86%).  We identified 14 studies which had a potentially high risk for 
contamination.  The majority of these (N=10) were identified as risk of contamination arising from a 
therapist in the intervention arm.   
Conclusion:  The risk of contamination framework we piloted in this study could be a helpful tool for 
researchers aiming to identify and manage risk of contamination in their trial protocol development.  
We found that the risk of contamination was relatively low in the psychological therapy trials we 
sampled for this study, as measured by our framework, and could usually be mitigated through 
reasonable adjustments to the study design.   
 






What is new 
• Contamination between intervention and control arms is often a concern in 
complex intervention trials because participants are often not masked to 
condition 
• We developed and tested out a simple framework tool that can be used at 
the stage of protocol development in clinical trials to assess the risk of 
contamination 
• We focused on the plausible routes by which contamination between arms 
might occur for more realistic risk assessment 
• We found that risk of contamination was low in 86% of sampled trial 
protocols, as measured by our tool. 
• Risk of contamination should be assessed at the protocol development stage 
of planning a trial, and using this standard framework would improve 
decision making around any necessary design adjustments required to 
reduce contamination risk 
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Introduction 
Complex healthcare interventions have been defined as interventions which are non-standard, have 
different forms in different contexts, but still conform to specific, theory-driven processes (Hawe, 
Sheill, & Riley, 2004).  Psychological therapies are considered a form of complex intervention due to 
having several interacting components and processes, which underpin the intervention (Magill, 
Knight, McCrone, Ismail, & Landau, 2019). The development and evaluation of high-quality complex 
healthcare interventions is dependent on the use of rigorous research methodology.  The Medical 
Research Council (MRC) (Craig et al., 2008) guidelines for complex intervention development and 
evaluation state that, wherever possible, it is best practice is to undertake an individually-randomised 
controlled trial (RCT) design in order to minimise bias. Individual RCTs minimise many forms of 
bias including selection bias, performance bias, detection bias, and attrition bias (Higgins & Green, 
2011), and thus are considered the most robust means of evaluating complex interventions. 
Wherever possible, RCTs are designed so that participants do not know whether they are 
receiving the intervention or the control treatment (often referred to as ‘single-blind’ in drug 
trials).  However, for psychological therapy trials it is less possible to mask participant 
allocation as a well-delivered collaborative therapy would involve full disclosure of the type 
of therapeutic intervention.  There may be some ability to mask the intervention if there is an 
active control, which is the delivery of non-specific therapy factors such as time and attention 
from an empathic therapist.  However, for psychological therapy trials where the control 
condition is a treatment as usual (TAU) or a waitlist control, participants may be much more 
likely to be able to accurately discern aware of which arm of the trial they are have been 
allocated to.  Given that masking to treatment allocation is often difficult to achieve in 
psychological therapy trials for these reasons, a concern that often arises at the design stage is 
that of how to minimise the risk of contamination. Contamination is the process whereby an 
intervention intended for members of one arm (the experimental intervention or treatment arm) is 
received by members of another (the control) (Keogh-Brown et al., 2007).  Participants in the control 
arm could potentially access treatment strategies from the intervention arm due to the intervention 
comprising transportable components which are difficult to confine (Magill et al., 2019).  This can 
lead to an underestimate of the true effectiveness of the intervention. Using a cluster randomised 
design is often suggested where the risk of contamination is judged to be considerable.  However, 
cluster randomised designs where groups, rather than individuals, are the unit of randomisation, are 
not without their drawbacks. Torgerson (2001) has argued that cluster randomised trials usually 
require much larger sample sizes, making them more expensive and time-consuming, and are 
susceptible to recruitment bias.  It is therefore important to first be sure that contamination is a real, 
rather than a hypothetical threat, before alternatives to individual randomisation are considered.  
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Previous studies have shown that contamination rates for complex intervention trials are not 
insignificant.  A large review of complex educational interventions (n=235) found a median level of 
24% contamination in participants (Keogh-Brown et al., 2007). Moreover, a recent systematic scoping 
review of 234 complex mental health intervention studies, identified contamination levels of 13% (of 
the 10% studies which reported on contamination) (Magill et al., 2019).   
Assessing the risk of contamination at the design stage of a psychological therapy trial is challenging.  
Identifying possible opportunities for contact between participants in the intervention and control 
arms is not sufficient to indicate a high risk of contamination in of itself.   This is because participants 
simply talking to one another about their therapy does not necessarily constitute contamination, unless 
it alters the behaviour of those in the control group in some meaningful way.   For example, the 
likelihood of participants being able to pass on psychological skills or strategies learnt within 
psychological therapy to control participants is unlikely, even when they are sharing a confined 
treatment environment (e.g. acute mental health inpatient ward).  Likelihood of transmission of the so-
called ‘active ingredients’ of a psychological therapy, via therapists or participants in the intervention 
arm, will depend on several factors, including what the intervention is, and how it is delivered.  For 
example, Magill et al. (2019)  identified in their review, that contamination was only a concern when 
clinicians were delivering treatment in both arms of the trial.  It has also been argued that substantial 
contamination can be tolerated before resorting to a cluster randomised trial, and that contamination 
can be dealt with appropriately in individual RCT designs, for example, through initial monitoring 
using a feasibility RCT, consideration of larger sample size and effect sizes (Torgerson, 2001).  Other 
methods for controlling of contamination have included ensuring that clinicians do not offer treatment 
across multiple trial arms, and informing participants only of the treatment they are receiving. 
Choosing appropriate design modifications to minimise any potential risk of contamination therefore 
includes a broader range of choices for the researcher than simply switching from an individual, to a 
cluster randomised design. To date however, there is no standard tool which researchers can use at the 
design stage of a psychological therapy trial to help guide these choices in an informed way.  The 
development and dissemination of such a tool could help researchers make proportionate decisions 
about how to minimise contamination risk, and to identify where processes are needed to monitor and 
record any contamination which may occur during the trial (e.g. recording therapy sessions in both 
intervention and control arm if delivered by the same therapist).  Our aim for the current study was 
therefore to develop a framework to assess potential risk of contamination in psychological therapy 
trials in mental healthcare, and to pilot it on a sample of protocols from a major trials registry to 
assess its utility. We also aimed to report on the strategies incorporated into the sample protocols to 
minimise contamination.  Our focus was on assessment of risk at the design phases of a trial (i.e. 
before a trial starts recruitment), and not assessment of any actual contamination which may have 
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Development of framework 
Initially, relevant literature was identified which explored the sources of contamination in trials of 
educational interventions, including a Delphi study of experts’ opinion. (Howe, Keogh-Brown, Miles, 
& Bachmann, 2007; Keogh-Brown et al., 2007) 
From this, we identified three main sources of contamination from their findings which would be 
applicable to mental healthcare trials.  These were: A) participant in control arm accesses treatment in 
the intervention arm themselves; B) participant in intervention arm passes treatment on to participant 
in control arm; C) therapist providing treatment in intervention arm passes treatment on to participant 
in control arm. In order to develop the framework, we identified examples of trial design which would 
exemplify either a high or low risk of contamination via each particular source (see supplementary 
material for a copy of the framework).  For example, for contamination source A, if the treatment in 
the intervention arm is freely available outside of the trial, such as a commercially available and 
widely-known therapy app, then a participant in the control group may access it themselves (high 
risk).  However, if the treatment involved a new app which was not yet commercially available, and 
required a personalised log-in provided by the trial team, then it is unlikely a participant in the control 
group could access it themselves (low risk).  Whilst recognising that a probabilistic risk assessment 
will always be on a spectrum to some degree from low to high risk, we decided to choose a binary 
rating scale in order to focus on a broad judgement of balance of probabilities, rather than an arbitrary 
quantitative rating.  We then piloted the framework on a representative sample of psychological trial 
protocols for mental healthcare trials from a major international trials registry (ISRCTN). 
Identification and selection of trial protocols 
We identified psychological therapy trial protocols on the ISRCTN registry (isrctn.com), with 
registration dates (date assigned), under mental and behavioural disorders, in the 24 months from 1st 
April 2016-31st March 2018.  Reasons for exclusion for trials categorised as mental and behavioural 
disorders, but not meeting criteria for psychological therapy trials as below, were recorded (see 
supplementary material for criteria).   
Data extraction and ratings of protocols 
We extracted relevant data from the ISRCTN record. This included general descriptive information 
about the trial, following the standard headings on the trial registry record (e.g. country of 
recruitment, recruitment target). Recruitment status and overall trial status (e.g. ongoing or 
completed) were correct as of date of data extraction (Sep-Nov 2018).  We referred to documents 
linked to the ISRCTN record on the website (e.g. journal paper of protocol, or published results) 
where they were available if we needed to supplement or clarify information in the trial record.  
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Where journal articles or other documents were not already linked to the record on the ISRCTN 
website we did not do a separate search. 
We first assessed all trial protocols using the TIDIER tool (Hoffmann, Glasziou, & Boutron, 2014), in 
order to report how well the intervention was described in the protocol.  This was relevant to the aims 
of the study, as information about how the intervention is delivered, and by whom, affects judgements 
about risk of contamination (e.g. whether the same or separate therapists are used in the intervention 
and control arms).  In line with the published guidance by Hoffman et al. (2014), we omitted items 10 
(modifications during study) and 12 (actual treatment fidelity) of the tool , as we were assessing 
protocols only, rather than reports of completed trials and these items are not applicable at the 
protocol stage.   
All trial registry records were independently double-rated by the authors PJ and LW, using both the 
TIDIER tool and the risk of contamination tool developed for this study.   Firstly, as part of a 
calibration and training check we each rated the first 10 records, then cross-referenced and discussed 
any discrepancies to reach a consensus.  We each then went on to independently rate the remaining 90 
records, before again cross-referencing and reaching a consensus after discussion on any ratings 
where there was a discrepancy.  For any studies which were identified as a potential high risk of 
contamination risk under any category (A-participant in control arm, B-participant in intervention 
aim, C-therapist in intervention arm), we also recorded whether there was any explicit reference to 
design modifications in the protocol to address any potential risks. 
Results 
Search results 
We found 2291 trial registry records with registration dates between April 2016 and March 2018, 325 
of which were categorised under ‘Mental and Behavioural Disorders’.  The first author (PJ) read the 
registry record for these 325 studies, and assessed them against the inclusion/exclusion criteria.  A 
total of N=225 studies were excluded at this stage, leaving N=100 studies meeting inclusion criteria as 
a psychological therapy trial for a mental healthcare condition.  These 100 studies went on to be 
double-rated by both authors as described in the method using 1) TIDIER tool and 2) risk of 
contamination tool.  The search process is shown in Figure 1 as a flow-diagram, following the 




Figure 1: Search Results from ISRCTN registry  
Trial registry records identified through 
ISRCTN database (24 months; April 2016-
March 2018)  































Trial registry records categorised as ‘Mental 
and Behavioural Disorders’  
(n = 325) 
Trial registry records meeting inclusion 
criteria for psychological therapy trials  
(n = 100) 





- Cognitive remediation 
(n=17) 
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and/or prevention 
strategies only in non-
clinical population 
(n=37) 
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- Service improvement, 







Trial registry records double-rated using  
1) TIDIER tool and 2) risk of contamination 
tool 
(n = 100) 
10 
Characteristics of included studies 
Included studies are summarised in Table 1.  Approximately half of trials were ongoing (48%), 
although only a quarter of them were still recruiting (24%).  Only half of trials were prospectively 
registered (51%).  The majority of trials were recruiting participants in Europe (82%), were 
government funded (45%), and recruited adults only (77%).  The most common treatment target was 
mood disorders (27%).  Trials were relatively small in size, with almost a third of studies reporting a 
recruitment target of 50 or less (29%) and only 24% of trials reporting a target of over 200 
participants.  The majority of trials were individually randomised controlled trials (77%), and used 
treatment as usual (TAU) as a comparator arm (37%).  The most common therapy type was cognitive-
behavioural therapy (61%), and was delivered on an individual basis (41%).  Although still a 
minority, we noted that a quarter of studies involved a digital health intervention (25%).  
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Table 1: Characteristics of included studies 



















Continent of Recruitment 
Europe 
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Continent of Study Sponsor 
Europe 
               - UK 
















Adults only (18+) 






Treatment target in ICD-10 categories 





F30-39 (Mood disorder) 
F40-49 (Anxiety disorders) 
F50-59 (Behavioural syndromes) 









































Randomised Controlled Trial (RCT)1 
Cluster RCT 
Non-randomised controlled trial 
Pilot/feasibility trial (no control group) 
 


















1 Includes 1 study with a 2nd non-RCT phase (patient preference allocation), and 1 study with 1 RCT site and 1 
non-RCT site 
2 Includes 1 study with a control condition described as ‘enhanced’ TAU 
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Combination of TAU, wait-list, and active 
control groups 









Combination treatments/multiple treatment arms 











Mode of therapy delivery (intervention arm) 




Combination of individual/group/family 
Group workshop with phone/self-help follow-up 
Digital intervention (e.g. web, app, text 
messages, VR) with some therapist/technician 
contact 
Digital intervention (e.g. web, app, text 






















Quality of intervention descriptions 
Assessment of studies using the TIDIER tool showed considerable disparity between how well 
interventions were described between different studies, and between different items on the TIDIER 
checklist across studies.  Results are summarised in Table 2.  Areas which were generally described 
well were the rationale for the therapy, what procedures were involved, in what modality the therapy 
was delivered, and when and how often the therapy was delivered.  However, we found that less than 
half of studies described any relevant therapy materials (37%), and only 57% of studies described 
who delivered the therapy.  Both of these aspects are important in assessing contamination risk, as 
they relate to how easily materials may be shared between the intervention and control arm, and 
whether they may be a risk of contamination arising from the same therapist delivering the therapy in 
both intervention and control arms of the trial.  On a related note, only a quarter (23%) of studies 
described plans for fidelity assessment, which may mitigate contamination risks, for example if 
therapy sessions are recorded and assessed for fidelity in the control arm.  
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1: Brief name 
 
48 (48%) 2 (2%) 50 (50%) 
2: Why (rationale)  
 
76 (76%) 0 (0%) 24 (24%) 
3: What_materials 
 
37 (37%) 31 (31%) 32 (32%) 
4: What_procedures 
 
60 (60%) 12 (12%) 28 (28%) 
5: Who provided  
 
57 (57%) 13 (13%) 30 (30%) 
6: How delivered  
 
95 (95%) 0 (0%) 5 (5%) 
7: Where delivered 
 
49 (49%) 37 (37%) 14 (14%) 
8: When and how often 
  
75 (75%) 5 (5%) 20 (20%) 
9: Tailoring described 
 
58 (58%) 34 (34%) 8 (8%) 
11: Fidelity 3assessment 
(planned) 
23 (23%) 56 (56%) 11 (11%) 
  
 
3 Not applicable in N=10 studies where intervention was self-help/digital only with no therapist contact 
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Risk of contamination ratings 
Overall, we found that the risk of contamination across all 3 sources (A-participant in control arm, B-
participant in intervention aim, C-therapist in intervention arm) was low for the majority of studies 
(86/100; 86%).  Of the remaining 14 studies, 2 were rated as potentially high risk for contamination 
source A (participant in control arm), 2 high risk for contamination source B (participant in 
intervention arm), and 10 high-risk for contamination source C (therapist in intervention arm).   No 
studies were rated as high-risk across more than one possible contamination source (A, B, or C).  
These 14 studies are further described in Table 3. 
Three examples, one for each source of contamination, will be described in this section for illustrative 
purposes.  The Nguvu trial (ISRCTN65771265), which was at high risk of contamination from source 
A (participant in control arm), involves an intervention delivered in refugee camps in Tanzania, which 
are organised into ‘villages’.  There was a potential contamination risk due to control participants 
being able to access the intervention groups within in refugee camps and the ethical challenges of 
restricting access to those in the control arm.  Therefore, the trial uses a cluster randomised design, so 
that villages are the unit of randomisation, which means that everyone living in the same village has 
access to the same intervention (either treatment or control condition).  For source B (participant in 
intervention arm), the PERSUADE trial (ISRCTN23278208) was considered at high risk.  This study 
involved participants attending an initial group workshop, followed by a self-help intervention using a 
workbook.  From the description in the protocol, we were not sure how generic or tailored the 
workbook, and therefore how easy it would be to pass on the materials and for them to be used 
meaningfully by a participant allocated to the control condition.  Participants were recruited from GP 
surgeries, so participants from intervention and control arms could conceivably be part of the same 
social network and have contact with each other.  Clustering by GP surgery would be an alternative 
design, but it was not clear if this had been considered by the research team.  The emotion focused 
therapy and cognitive behavioural therapy trial for treatment of generalised anxiety disorder 
(ISRCTN52689081) was at high risk of source C contamination (therapist in intervention arm).  This 
trial was going to use the same routine care therapists to deliver both interventions.  Risk of 
contamination was rated as high given the potential for intervention strategies to be delivered in the 
incorrect arm by the therapists.  The authors mitigated against this risk by planning to audio recording 
all therapy sessions, and for a sample of sessions to be rated by independent raters.
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Discussion 
This study aimed to develop a framework to identify risk of contamination in psychological therapy 
trials in mental health care, to inform study protocol development. A framework was developed which 
examined three key areas of contamination: contamination from participant in control arm accessing 
the intervention arm themselves, participants in the intervention arm passes treatment on to participant 
in control arm, and therapist providing treatment in intervention arm passes treatment on to participant 
in control arm.  Application of the framework to 100 trial protocols identified that all possible sources 
of contamination were captured by the framework, demonstrating its applicability to identifying 
contamination risk in psychological therapy trial protocols in mental health care.  Overall, this 
framework could be a helpful tool for researchers aiming to identify and manage risk of 
contamination in their trial protocol development.  It should be noted that we only aimed to assess risk 
of contamination, and this should not be confused with any kind of ‘quality assessment’ in terms of 
assessing the protocols.  Some studies identified as potentially at risk of contamination could 
nonetheless be considered high quality, robustly designed studies, with clearly written protocols. 
The findings demonstrated that risk of contamination was relatively low across studies and only 
present in 14% of examined protocols.  However, when a high contamination risk was identified, the 
contamination risk predominantly came from the therapist (10/14; 71%).  More specifically, therapists 
were often described as delivering the intervention across trial arms or having some contact with 
participants across both arms of the study.  A similar finding was identified in a recent study by 
Magill et al. (2019) who examined complex intervention trials in mental health care.  They identified 
that key areas of contamination related to clinical staff involvement in the trial. This included staff 
delivering interventions in both arms, clinical staff not delivering the intervention but still treating 
participants in both arms as part of routine care and therefore learning about the intervention and 
passing it onto participants, and trial clinical staff communicating between trial arms.  This finding 
demonstrates the importance of incorporating strategies into the study design to minimise this form of 
contamination.  A number of primary protocol papers had explicitly included strategies for managing 
contamination including, therapists not delivering interventions in multiple arms, and therapists 
delivering interventions in different arms having no communication about the intervention.  It should 
be noted however, that using the TIDIER tool, only 57% of protocols in our sample had a clear 
description of who delivered the intervention.  We did not automatically categorise a protocol as at 
high risk of therapist-related contamination when it was not clear who was delivering the intervention.  
The actual proportion of protocols with a risk of therapist-related contamination may therefore have 
been higher if we had had full information on who was delivering the intervention in 100% of the 
sample.  However, this limitation would not be applicable to the primary purpose of the framework as 
a tool to help in the design of trial protocols, as the research team would know who was delivering the 
intervention, even if they went on to report it inadequately in the trial registry record. 
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The review identified that cluster randomised control designs were only required when the 
psychological intervention was widely available or easily transferred between trial arms.  This was the 
case across all contamination categories.  For example, in regard to therapist contamination, cluster 
randomisation was only considered when there was no other means of ensuring that the therapy was 
delivered by separate clinician across arms, e.g. an intervention being delivered by clinicians in 
routine care (e.g. ISRCTN38120107).  With regards to participant contamination, cluster 
randomisation was only considered when all participants would potentially have access to the 
intervention due to it being widely available (e.g. routinely run groups in refugee camps 
(ISRCTN65771265), or open access online intervention (ISRCTN11086185), or from intervention 
participants being able to share self-help material (self-help material for refugees in a refugee camp; 
ISRCTN50148022).  We therefore hope that this framework would be helpful in identifying less 
obvious routes of contamination, which may arise from participants in the trial sharing access to 
components of the intervention because they come from the same geographic location and/or social 
network.  It is not unknown in these cases for participants in the intervention arm to recommend the 
trial to others in their network, and encourage others to sign up.  Even if the ‘new recruits’ are 
subsequently allocated to the control arm, they may still gain access to materials from the intervention 
arm through their personal contact with existing trial participants.  However, we would suggest that 
cluster randomised control designs are not required when the intervention accessibility is limited and 
complex to deliver (e.g. a psychological intervention from a highly trained therapist), as this cannot be 
‘shared’ between participants in the same way as a self-help booklet could be.  Given the potential 
drawbacks of implementing a cluster randomised controlled design in terms of sample size and 
recruitment bias, this suggests that cluster randomisation should only be used when necessary where 
other methodological adaptation do not mitigate contamination risk. It is important to acknowledge of 
course, that there may be several valid reasons for choosing a cluster randomised design, other than to 
protect against contamination (e.g. for interventions which are naturally delivered at cluster level such 
as in educational settings). 
There are a number of strengths to this study.  This is the first study, which we are aware, that has 
developed and implemented a framework to examine contamination risk in psychological therapy 
trials for mental health care, to inform protocol design.  The framework will provide a useful guide to 
minimise contamination risk in future psychological therapy trials.  Moreover, it has been applied to a 
wide array of psychological therapies demonstrating its broad applicability.   We did limit the trial 
protocols in this sample to a narrow definition of psychological therapy, excluding for example, 
interventions which consisted of psychoeducation or peer support only.  We are not suggesting that 
the framework would not be relevant to these types of trials, but this would need to be explored in 
further research.  Although we have chosen to focus on the use of the tool for mental healthcare trials 
for the purposes of this paper, this framework should be equally applicable to other contexts, such as 
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non-pharmacological interventions in physical healthcare, public healthcare and educational 
interventions. To examine the framework for its applicability to broader health care interventions, 
further implementation would be required.  As outlined, this framework was devised to be used as a 
simple tool to inform study protocol development, not a specific guideline; therefore a limitation is 
that it did not go through the methodologically rigorous process expected for guideline development 
(Moher, Schulz, Simera, & Altman, 2010).  However, the categories of contamination were informed 
by relevant literature, including a large rigorous study examining contamination in educational 
interventions (Keogh-Brown et al., 2007).   
In conclusion, this framework is a helpful tool in examining contamination risk in psychological 
therapy trials for mental health care.  The framework identified that risk of contamination is relatively 
low in psychological therapy trials and often can be mitigated again through adjustments to the study 
design.  Cluster, rather than individually randomised controlled trials, are only required to protect 
against contamination when the intervention is widely available or easily transferrable and not 
warranted for complex interventions delivered by highly trained therapists.    
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1. Inclusion/Exclusion Criteria for trial protocols 
 
2. Framework for assessing likely risk of contamination in psychological therapy trials 
 




Inclusion Criteria for trial protocols  
i. Individual, group or family therapies, delivered in any setting, and via any modality (e.g. face 
to face, online, telephone).   
ii. Therapies aimed at children, adolescents, adults or a mixture.    
iii. Therapies aimed at ICD-10 F10-F69 disorders (substance misuse, schizophrenia-spectrum, 
mood disorders, neurotic disorders, behavioural syndromes (including eating disorders) and 
personality disorders).  Target populations did not necessarily need to meet threshold for 
diagnosis, have received a formal diagnosis, or be in receipt of mental health services.  
Interventions aimed at people with physical health conditions, organic disorders, 
neurodevelopmental or neurodegenerative disorders were included only if they had additional 
psychological disorders falling into F10-F69 categories (e.g. depression in people with 
multiple sclerosis).  
iv. Any comparator arm (e.g. TAU, active control, other treatment including medication)  
v. Feasibility/pilot trials without a control arm (on the basis that a subsequent efficacy trial 
would likely include a control arm).    
Exclusion Criteria for trial protocols  
i. Interventions consisting solely of psychoeducation, peer-support, self-management of 
condition, management of condition via parent/carer, or focused solely on improving 
parenting/carer skills, which are not part of a broader psychological therapy based on an 
explicit theoretical model.  
ii. Interventions aimed solely at remediation or enhancement of cognitive functioning (e.g.  
Cognitive Remediation Therapy).  
iii. Therapies aimed at ICD-10 disorders outside of F10-69 range, or primary outcome target is 
not mental-health (e.g. educational attainment, physical activity levels).  
iv. Interventions aimed at improving well-being or reducing stress in non-clinical populations 
(e.g. general public, health-care staff, carers, school children, university students), or aimed 
solely at prevention of mental health disorders.  
v. Interventions consisting solely of an ‘Investigational Medicinal Product’ (IMP) and/or 
nontalking therapies or interventions (e.g. arts therapies, acupuncture, exercise).  
vi. Non-interventional studies, such as diagnosis, assessment, screening or identification of 
factors which later predict development of a mental health disorder.    
vii. Studies focusing on service improvement, staff training, or implementation only.  




Framework for assessing likely risk of contamination in psychological therapy trials 
Source of contamination High-Risk Low-Risk 
Participant in control arm 







• Therapy/intervention is 
freely available, easy to 
access outside of trial, 
and free or low-cost  




• Hard to gate keep 
access to 
therapy/intervention on 
ethical or practical 
grounds 
 (e.g. therapy groups in 
communal areas on 
psychiatric wards)  
• Therapy/intervention is 
not widely available, or 
is prohibitively 
expensive 
(e.g. long waiting lists for 





team are sole gate 
keepers to intervention 
(e.g. new therapy 
manual/protocol which is not 
yet used in routine clinical 
practice) 




• Therapy/intervention is 
single-faceted, easily 






• No specific skills or 
training required to 
deliver intervention 
(e.g. self-help booklet) 
• Therapy/intervention is 
multi-faceted, cannot be 
easily passed on, and is 
individually tailored 




• High degree of skills 
and training required 
to deliver intervention 
(e.g. trial therapists have 
established competencies in 
intervention they are 
delivering) 
C: Therapist who is providing 
treatment in intervention arm 
• Intervention consists of 
training therapist in a 
new skill which cannot 
be unlearnt/easily 
switched off 





Same therapist in 
intervention/control 
arm (e.g. single therapist 
trial) 
• Intervention consists of 
discrete components 
which can be delivered 
according to a standard 
manual/protocol 
(e.g. use of behavioural 
experiments in CBT for 
anxiety) 
 
Separate therapists for 
intervention/control 
arm, or minimal 
overlap in staff working 
with participants in 
both arms of the trial 
(e.g. trial therapists 
deliver intervention, 
routine clinical staff 
deliver TAU) 
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study design to 







1. Nguvu: Evaluating 
an integrated 




in refugees in 
Tanzania 
Cluster RCT Cluster 
randomised 
design  
Intervention is designed to be provided in refugee 
camps, via pre-existing women's groups across 
different villages.  Trial protocol notes that it would 
not be ethical or practical to try and exclude women 
who had been allocated to the control arm, from 
accessing groups within the same village for 
participants in the intervention arm, if the trial was 
designed with individual participant randomisation.  
Therefore the village is the unit of randomisation 
(village=cluster). Separate caseworkers deliver 
intervention and treatment as usual (TAU) across the 
different villages. 
ISRCTN11086185 2. CANreduce 2.0 - 
comparing two 
differently optimized 
versions of a web-
based self-help 





from same IP 
address are 
blocked 
Study compares 2 forms of web-based intervention 
(enhanced with unenhanced) with a wait-list control.  
A participant allocated to the control group could 
possibly try and re-register to get access to the 
intervention programme, but this risk has been 
addressed in the protocol by blocking multiple 
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cannabis use with 
each other and a 
waiting list 
attempts from the same IP address.  Each participant 
receives a personal log-in and people can work through 
modules in their own time and order, so risk of 
contamination by participant in the treatment arm is 
low, as the intervention is not easily shared.  Response 
to e-mail queries is only available in 1 arm of trial, so 
there is no risk of contamination from the therapist. 
B:  Participant in 
intervention arm 
ISRCTN50148022 3. Self-help plus 
(SH+) for South 
Sudanese refugees in 
Uganda 
Cluster RCT Cluster 
randomised 
design 
Intervention is based on self-help delivery within a 
refugee camp, so materials could easily be shared by 
participants in the intervention arm, with participants 
in the control arm, if they were within the same 
refugee camp.  Therefore the village is the unit of 
randomisation (village=cluster), so participants in the 
intervention arm do not have close contact with people 
allocated to the control arm. 
ISRCTN23278208 4. Preventing 
depression study: 
PERSUADE 
RCT None noted in 
protocol 
Participants attend an initial group workshop (8 hours 
over 1-2 days), then are given a self-help workbook to 
use (expected time commitment not stated).  It is not 
clear from the protocol how tailored/generic the 
workbook is, and therefore, how feasible it would be 
for participants in the treatment arm to share it with a 
participant in the control arm (TIDIER item 3).  
Contact between participants in intervention and 
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control arms could be possible as participants are 
recruited through GP surgeries, and people from the 
same family or belonging to the same social networks 
may be registered at the same GP practice as one 
another.  
C: Therapist in 
Intervention Arm 
ISRCTN40388402 5. Violence and 
alcohol abuse 
intervention for 




RCT None noted in 
protocol 
It is not possible to determine from the trial protocol 
whether staff (social worker/midwife) involved in 
delivering the intervention arm treatment also have 
contact with participants in the control group. This is 
important as staff training in the intervention 
(motivational interviewing; MI) could possibly lead to 
these techniques or skills being used by the same staff 
during standard contacts with participants in the 
control group.  There is no reference to recording 
sessions in the control arm, which could help detect 
any contamination should it arise. 
ISRCTN16382776 8. Mindfulness Based 
Cognitive Therapy 
(MBCT) programme 
for depression in 
people with early 
stages of dementia 
RCT None noted in 
protocol 
There are no details in the trial protocol about who 
delivers the intervention (TIDIER item 5). If routine 
clinical staff were recruited and trained to deliver the 
intervention, it is possible they might start to introduce 
mindfulness exercises in other clinical contact they 
have with control group.  This would not a be a 
concern if the MBCT intervention was delivered by 
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separate trial therapists, who were not part of the 
routine clinical team, or if a cluster randomised design 
was used.  However, the MBCT intervention is a 
complex intervention, comprising several components, 
and so access to isolated components by participants in 
the control group (e.g. mindfulness practises, but 
without teacher-led enquiry) may not in themselves be 
seen to be a significant contamination threat. 
  





reduce substance use 
in adolescents who 
are involved in the 
criminal justice 
system in the UK 
RCT 
 
None noted in 
protocol 
The trial protocol states that the intervention is 
delivered by youth workers trained in motivational 
interviewing (MI), who are then given extra training in 
the trial intervention (RISKIT-CJS).  RISKIT-CJS is 
described as a multi-component psychosocial 
intervention designed to reduce substance misuse in 
adolescents who are involved in the criminal justice 
system in the UK.  The CBT components include MI, 
psycho-education, anger management, assertiveness 
training, mindfulness, & planning for the future.  It is 
not clear whether youth workers delivering the 
intervention in the treatment arm might have contact 
with participants in the control arm, if they were 
service users of the same youth offending team.  If so, 
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there could be the potential for contamination arising 
from youth workers providing aspects of the 
intervention to participants in the control group.  A 
cluster-randomised design might be a possible solution 
to this. 
ISRCTN12077707 10. DECRYPT: 
Delivery of cognitive 
therapy for young 
people after trauma 







in the control 
group 
Possible risk of therapist contamination given 
pragmatic trial design (routine clinicians deliver the 
therapy in the intervention arm).  This possible risk is 
specifically addressed in the protocol however, as it 
states that there would be no contact between 
clinicians delivering the trial therapy, and participants 
in the control group (who just receive TAU). 
ISRCTN60291091 11. Brief 
interventions to 
reduce risky drinking 
in parents of children 
referred to children’s 
social care 
Cluster RCT Cluster 
randomised 
design 
The unit of randomisation is the social care 
practitioner, as a single practitioner works with all 
family members (this will prevent within family 
contamination).  Practitioners in the control group 
receive no extra training in the intervention from the 
treatment arm of the trial (alcohol intervention). 
ISRCTN17852603 12. Mindfulness for 
paranoia 
RCT None stated in 
protocol 
It is not clear in the trial protocol exactly who delivers 
the intervention (TIDIER item 5).  The protocol refers 
to 2 therapists, but it is not made explicit whether these 
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are clinicians involved in providing routine clinical 
care, who might also have contact with participants in 
the control group.  This would not a be a concern if the 
mindfulness groups were delivered by separate trial 
therapists, who were not part of the routine clinical 
team, or if a cluster randomised design was used.  
However, the intervention is a complex intervention, 
comprising several components, and so access to 
isolated components by participants in the control 
group (e.g. mindfulness practises, but without teacher-
led enquiry) may not in themselves be seen to be a 
significant contamination threat. 
ISRCTN12268776 13. A study of 
Acceptance and 
Commitment 
Therapy for older 
people with chronic 




ty trial (with 
no control 
group) 
N/A  - current 
study does not 
have a control 
group 
If the pilot trial was successful, and led onto a future 
RCT, there could be a potential risk of contamination 
if the therapists providing the intervention also had 
contact with, or provided care for, participants in the 
control group. The potential contamination risk would 
also depend on what the control arm was, i.e. whether 
it was TAU or an active therapy control. 
ISRCTN38129107 14. The coaching for 
smokers trial 
Cluster RCT Cluster 
randomised 
design 
The unit of randomisation is the GP, who receives 
extra training and delivers the intervention.  The trial 
protocol notes that a cluster randomisation design is 
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required, as it may be difficult for GPs to switch 
between the control/treatment approaches between 
different patients. 








RCT Fidelity checks 
in both arms of 
the trial (therapy 
sessions are 
audio-taped) 
As the same routine care therapists provide therapy in 
both arms of the trial, there is a possibility of 
contamination by the therapist, but the trial protocol 
notes there are plans in place to check treatment 
fidelity in both arms of the trial.  Sessions are audio-
recorded for fidelity checks, and a sample of sessions 
from all therapists are rated by at least 2 independent 
raters. 











RCT None stated in 
protocol 
The main difference between the therapies in the 
intervention and control arms is whether eye 
movements are used.  The trial protocol does not 
describe who delivers the intervention (TIDIER item 
5).    If the same therapists deliver treatment in both 
arms of the trial, it is possible that eye movements 
could be delivered accidentally in the control arm.  The 
trial protocol does not mention any plans for fidelity 
checks (TIDIER item 11), which could help provide 
data on whether any actual contamination occurred in 
the control group. 
 
